| At a Glance | |
|---|---|
| Who it's for | Experienced users training 4+ days/week who want fat loss without giving up performance |
| Duration | 12 weeks |
| Key components | Retatrutide (0.25–4 mg/wk), NAD+, L-Carnitine, MOTS-c, Tesamorelin |
| Results timeline | Visible recomposition can emerge by weeks 4–8 when training, protein, sleep, and titration are controlled |
| Difficulty | Advanced |
This is an advanced-level protocol. It assumes consistent training (4+ days per week), adequate protein intake, and discipline with multi-compound stacks. For a simpler starting point, see the Retatrutide + NAD+ support protocol.
The Problem with GLP-1 Monotherapy
GLP-1 agonists work—the appetite suppression is real, the deficit follows. But something is wrong with the outcomes.
People can get lighter but weaker. Thinner but exhausted. The scale moves, but energy does not follow. In the matched non-T2D DXA anchors, semaglutide's STEP-1 lean fraction was roughly 38–39% of fat-plus-lean loss, while tirzepatide's SURMOUNT-1 DXA lean fraction was about 25%.¹ That does not mean muscle loss is inevitable. It means protein, training, dose discipline, and repair support decide whether the deficit looks like fat loss or mixed tissue loss.
GLP-1 drugs create deficits by suppressing appetite. But a deficit is pressure, not direction. Without enough training signal, protein, recovery, and oxidation capacity, the weight lost can include too much lean tissue.
Weight loss requires two axes working together:
- Central axis — appetite, intake behavior, the decision to eat. GLP-1s address this effectively.
- Peripheral axis — oxidation machinery, mitochondrial capacity, the ability to burn what's been mobilized. GLP-1s do not automatically solve this axis.
This is why GLP-1 monotherapy can produce weight loss without high-quality recomposition.
Why Retatrutide Is Different
Retatrutide engages three receptors at strengths no natural combination produces: GIP much harder than your body's own (the dominant arm), GLP-1 softer (less nausea), and glucagon softer still. The third receptor — glucagon — is what separates retatrutide from its predecessors.
Glucagon receptor activation actively mobilizes stored fat. The liver is signaled to oxidize its existing triglyceride stores rather than relying on a caloric deficit to drain them passively. Sanyal 2024 confirmed this directly: β-hydroxybutyrate (the biomarker for hepatic fatty-acid oxidation) rose +93% at 4 mg and +181% at 12 mg — the signature of active glucagon-driven lipid mobilization, not a downstream consequence of weight loss.
But the glucagon arm is dose-gated. Its peripheral effects - heart-rate elevation, sustained lipolysis, chills, and the broader tissue-weakening pressure that can put lean mass at risk - rise as dose and titration speed rise. At 0.25–4 mg, the hepatic signal can be useful, but lean and sensitive users can still feel heart-rate or autonomic effects early.
At high doses (8–12 mg), retatrutide behaves more like a maximum weight-loss drug: peak weight loss, higher glucagon-class side-effect burden, and more support burden. This protocol uses retatrutide differently: as a low-dose metabolic controller. For many recomp users, that means 0.25–2 mg. Some advanced users may move toward 4 mg, but only after long holds and clean tolerance.
The Fat-Burning Chain
Fat burning is not one step. It is a chain, and each link matters:
- Retatrutide → releases fat from storage (mobilization)
- L-Carnitine → transports fat into mitochondria (logistics)
- MOTS-c → programs mitochondria to prefer fat (the switch)
- NAD+ → provides capacity to complete combustion (execution)
If one link is missing, the stack becomes less efficient and harder to tolerate.
Retatrutide Mobilizes Fat
The glucagon arm pushes the liver toward active fat oxidation — Sanyal 2024 measured β-hydroxybutyrate elevation of +93% at 4 mg and +181% at 12 mg, a marker of hepatic fatty-acid oxidation.⁶ Fat leaving storage is not the same as fat being fully burned. The downstream chain (transport, mitochondrial preference, NAD+ cofactor capacity) determines whether mobilized fat becomes usable energy.
L-Carnitine Transports Fat
Long-chain fatty acids cannot cross the inner mitochondrial membrane on their own. They require the carnitine shuttle.⁴ Without adequate carnitine, fatty acids can remain outside the mitochondria instead of being moved into the oxidation pathway.
Read about L-Carnitine
MOTS-c Programs Mitochondria
Fat sitting inside mitochondria is not the same as fat being oxidized.
Mitochondria can burn either glucose or fat. In metabolically inflexible individuals, the system is biased toward glucose. Fat may be present, transported, available, but the machinery isn't set up to prefer it.
MOTS-c is a mitochondrial-derived peptide that activates AMPK³, the energy sensor that detects active fuel burning. AMPK triggers pathways that shift cellular preference toward fat oxidation. The mitochondria stop waiting for glucose and start burning what's available.
This is not stimulation. It is reprogramming.
NAD+ Completes Combustion
Once mitochondria are programmed to prefer fat, they need cofactor capacity to complete beta-oxidation. NAD+ is the electron carrier that fat oxidation spends every cycle.⁵ Without enough NAD+ availability or recycling capacity, the chain can bottleneck: fat is mobilized, transported, and queued for burning, but the user feels underpowered.
The subjective experience is fatigue, brain fog, and the sense of being "wired but underpowered."
Understand why NAD+ is a critical support layer for GLP-1s.
The Anabolic Layer: Tesamorelin
The first four layers create a deficit and route it toward fat. But they do not actively protect lean tissue. Under strong catabolic pressure, the body can still pull from lean mass.
Tesamorelin adds the anabolic counterweight. It's a GHRH analog that restores pulsatile growth hormone secretion rather than supplying exogenous GH. The distinction matters: tesamorelin preserves the body's natural rhythm rather than flattening it.
In clinical trials, tesamorelin produces selective effects:²
- Visceral adipose tissue decreases
- Lean mass is preserved or modestly increased
- Hepatic fat fraction drops
The visceral fat reduction creates a feedback loop. Visceral fat secretes inflammatory cytokines, worsens insulin resistance, and impairs fuel-routing. As visceral fat decreases, insulin sensitivity improves, and the fat-as-fuel bias becomes easier to maintain.
Circadian alignment matters: GH secretion is naturally nocturnal. Tesamorelin amplifies this pattern, supporting a clean division — daytime for AMPK-dominant oxidation, nighttime for mTOR-dominant repair.
Alternatives and Add-Ons
Ipamorelin is the modern GHRP choice when tesamorelin is unavailable or when a GH-pulse amplifier is needed — see the GH secretagogue comparison. It drives a short ghrelin-receptor GH pulse with less cortisol, ACTH, prolactin, appetite, and histamine noise than older GHRPs. It is usually dosed 100–300 mcg SubQ before bed, ideally at least 2 hours after food and 60–90 minutes before sleep. It can also be combined with tesamorelin when a stronger GH pulse is appropriate.
AOD-9604 targets stubborn subcutaneous fat depots directly. It's the lipolytic fragment of growth hormone (amino acids 176–191) — it signals fat cells to mobilize stored energy without raising IGF-1 or affecting insulin sensitivity. Clinical efficacy as a standalone is modest (~2% net difference in Phase 2b), but as a fine-tuning adjunct layered on top of the oxidation chain, it addresses the last-mile problem of resistant fat deposits. Dosing: 300 mcg SubQ fasted AM. Has FDA GRAS status as a food ingredient, reflecting favorable safety review.
Dosing
Use the reconstitution calculator to determine exact injection volumes for each compound.
| Compound | Dose | Frequency | Route | Timing |
|---|---|---|---|---|
| Retatrutide | 0.25–4 mg | Weekly or every 3d | SubQ | Same schedule each week |
| NAD+ | 100–250 mg | 2–3×/week | IM preferred; SubQ lower/split | Morning or mid-day |
| L-Carnitine | 200–500 mg | 5–7×/week | IM | Fasted, or pre-training |
| MOTS-c | 5–10 mg | 2–3×/week | SubQ | Fasted, pre-training |
| Tesamorelin | 1–2 mg | Nightly | SubQ | Before sleep, 2+ hrs after last meal |
Retatrutide should hold each step for 4+ weeks, without increasing through active side effects. NAD+ should be pushed slowly; dilute or split if local burn dominates. L-Carnitine can move toward 1000 mg briefly as a loading option, but 200–500 mg is the normal working range. Monitor IGF-1 at weeks 4 and 12 if using Tesamorelin.
Use separate syringes. This stack is an architecture, not a cocktail vial.
Weekly Schedule (Example)
| Compound | Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|---|
| Retatrutide | 1–2 mg | — | — | — | — | — | — |
| NAD+ | 150 mg | — | 150 mg | — | 150 mg | — | — |
| L-Carnitine | 500 mg | 500 mg | 500 mg | 500 mg | 500 mg | opt | — |
| MOTS-c | 10 mg | — | 10 mg | — | 10 mg | — | — |
| Tesamorelin | 2 mg | 2 mg | 2 mg | 2 mg | 2 mg | 2 mg | 2 mg |
Note: MOTS-c activates AMPK–PGC1α transcription for ~72 hours. An activated pathway does not need re-activation. Little benefit is gained by increasing frequency.
| Phase | Duration | Protocol |
|---|---|---|
| On | 4–6 weeks | 5–10 mg, 2–3×/week |
| Off | 2–4 weeks | Continue other compounds |
Lifestyle Foundation
| Component | Target |
|---|---|
| Protein | 1.0–1.2 g/lb body weight; 30–40 g per meal |
| Carbohydrates | Increased intake of fruit before training |
| Training | 4–5 days/week; resistance + Zone 2 cardio |
| Cardio timing | Fasted morning after L-Carnitine for optimal oxidation |
| Sleep | 7–9 hours; Tesamorelin timing requires consistent bedtime |
| Hydration | 3–4 liters daily |
Timeline: What to Expect
Weeks 1–4
- GH adaptation — Sleep deepens within first week
- Fat loss — Appetite, waist, and training tolerance start to show whether the dose is adequate
- Recovery — Training recovery noticeably faster
- Water — GH-related retention may occur; resolves by week 3–4
- Muscle — Fullness maintained despite deficit
Weeks 5–8
- Recomposition — Waist drops while strength and limb fullness hold
- Performance — Strength is maintained or improves; endurance may rise
- Visceral fat — Belt notches move; trunk tightens
- Energy — Often steadier than expected despite lower intake
Weeks 9–12
- Definition — Stubborn areas may begin to move if training, sleep, and intake are consistent
- Cumulative — Fat loss and lean-mass preservation depend on training, protein, sleep, and dose discipline
- Metabolic markers — Glucose, triglycerides, HDL, and liver enzymes may improve
- State — The protocol should feel tolerable, not like a constant fight against side effects
A Note on These Projections
The outcomes above are practical expectations, not a trial promise. Retatrutide's first Phase 3 readout used a very different population and a higher-dose weight-loss frame. No clinical trial has tested this exact protocol. The rationale comes from receptor pharmacology, body-composition evidence, NAD+ substrate biology, GH-axis data, and field convergence. Individual results depend on training, protein, sleep, dose discipline, and starting phenotype.
When Progress Stalls
| Step | Action |
|---|---|
| 1 | Verify protein intake, carbohydrate floor, steps, and sleep quality |
| 2 | Confirm retatrutide side effects are quiet before changing the dose |
| 3 | Increase L-Carnitine toward 500–1000 mg/day if fatty-acid transport is the bottleneck |
| 4 | Move NAD+ toward 250 mg per dose, or improve dilution / route if irritation limits use |
| 5 | Add one Zone 2 cardio session |
| 6 | For stubborn subcutaneous fat: consider AOD-9604 300 mcg fasted AM |
Managing Side Effects
GH-Related (Tesamorelin)
| Issue | Management |
|---|---|
| Water retention (weeks 1–3) | Transient; ensure adequate potassium |
| Joint stiffness / hand paresthesia | Improves with movement; reduce dose if persistent |
| Blood glucose elevation | Monitor if diabetic; GH can transiently raise fasting glucose |
Retatrutide-Related
| Issue | Management |
|---|---|
| Nausea/early satiety | Smaller protein-first meals; hold dose |
| Constipation | Fiber + fluids → magnesium citrate |
| Resting HR increase | Hold dose; track morning resting HR |
| Chills or skin sensitivity | Hold or step back; do not titrate through it |
MOTS-c/L-Carnitine
| Issue | Management |
|---|---|
| Early fatigue (MOTS-c) | Usually resolves; ensure food timing, sleep, and electrolytes |
| Injection site soreness | Rotate sites; slow push; split larger NAD+ SubQ doses |
Monitoring
| Timepoint | What to Track |
|---|---|
| Baseline | CBC, CMP, lipids, fasting glucose/insulin, HbA1c, thyroid, IGF-1, resting HR/BP |
| Week 4 | IGF-1 (target physiologic elevation, not supraphysiologic), fasting glucose, resting HR |
| Monthly | IGF-1 while on Tesamorelin |
| Week 12 | Full panel; glucose, TG, HDL, IGF-1, liver enzymes, thyroid if fatigue/cold intolerance appears |
IGF-1 guidance: Target physiologic elevation. If IGF-1 exceeds 350–400 ng/mL, reduce Tesamorelin dose.
What Comes Next
Maintenance:
- Reduce retatrutide to the lowest effective dose, often 0.5–2 mg/week for recomp users
- Tesamorelin to 1 mg nightly for sleep/connective tissue support
- NAD+ at 100–150 mg 2-3x a week
- L-Carnitine pre-training as needed
Lean-gain phase:
- Reduce retatrutide to the minimum effective dose
- Maintain Tesamorelin
- Increase calories to slight surplus
- Continue NAD+ and L-Carnitine
- Goal: slow, clean accrual of lean mass
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Active malignancy (GH/IGF-1 axis; MOTS-c)
- Proliferative diabetic retinopathy
- Pregnancy or breastfeeding
- Uncontrolled diabetes (requires close monitoring)
- Pre-existing atrial fibrillation, structural heart disease, or sustained unexplained tachycardia without clinician oversight
FAQ
Why use low-dose retatrutide instead of full dose?
Full-dose retatrutide (8–12 mg) pushes deeper into the glucagon-class side-effect zone: higher heart-rate signal, stronger fat mobilization, more chills or skin sensitivity, and more tissue-weakening pressure if nutrition and training are not controlled. Low-dose retatrutide keeps the GIP-forward signal active while leaving room for training, protein intake, and the lean-preservation layer to do their work. The recomp window depends on that distinction.
Can I skip the anabolic layer (Tesamorelin)?
You can, but the protocol becomes more weight-loss oriented and less recomp-oriented. Tesamorelin supplies the nighttime growth-hormone signal that supports lean tissue, connective tissue, sleep-linked recovery, and visceral-fat targeting during a deficit.
How do I know if the protocol is working?
Track waist circumference and strength performance, not just scale weight. Recomposition often shows as stable or dropping weight with maintained or increased strength and smaller waist.
What happens after 12 weeks?
Transition to maintenance (lower doses) or a lean-gain phase (reduce retatrutide to 1–2 mg/week, maintain tesamorelin, slight caloric surplus). The metabolic improvements persist if habits are maintained.
What does MOTS-c do in this protocol?
MOTS-c pushes cells toward the same adaptation pattern triggered by endurance training: better mitochondrial capacity and stronger preference for fat use (AMPK signaling³). In this stack, retatrutide mobilizes fat and L-Carnitine transports it into mitochondria; MOTS-c helps the machinery use that fuel instead of defaulting back toward glucose.
MOTS-c is dosed 2-3 times per week because the downstream adaptation signal lasts roughly 72 hours. The protocol cycles it 4-6 weeks on, 2-4 weeks off, while other compounds continue.
Why isn't oral L-Carnitine part of this stack?
Long-chain fatty acids cannot cross the inner mitochondrial membrane on their own — they require the carnitine shuttle system to get inside the furnace. When retatrutide's glucagon arm mobilizes fat from storage, that fat enters the bloodstream but is not yet being burned. Without adequate carnitine, fatty acids accumulate outside the mitochondria, unavailable for oxidation.
This protocol uses injectable L-Carnitine rather than oral because intramuscular delivery bypasses the gut absorption limits that make oral carnitine less reliable. The working range is usually 200–500 mg IM, fasted or pre-training; 1000 mg daily is a short loading option, not the default.
Why does NAD+ matter during aggressive fat loss?
NAD+ is the redox cofactor beta-oxidation spends while breaking fatty acids down inside mitochondria. When the rest of this stack mobilizes, transports, and signals fat for burning, NAD+ availability becomes load-bearing. If the pool is low or demand outruns recycling, the subjective pattern is fatigue, brain fog, and feeling "wired but underpowered."
Aggressive deficits also increase NAD+ demand. This protocol uses 100–250 mg IM 2-3 times per week as the default. SubQ is acceptable for users who prefer it, but lower or split doses are often better tolerated. During maintenance, NAD+ usually drops to 100–150 mg weekly or 2 times per week depending on fatigue, training load, and oral precursor use.
Related Topics
- Retatrutide Guide — mechanism, trials, and safety data
- Retatrutide Dosing Calculator — reconstitution math for 10/12/24mg vials
- Retatrutide vs. Tirzepatide — head-to-head mechanism and weight-loss differential
- Retatrutide + NAD+ support protocol — simpler starting point
- GLP-1 Hub — broader GLP-1 family coverage
- GLP-1 Compounds Tool — interactive comparison with trial data on weight loss and composition
- Tesamorelin Guide — the anabolic layer explained
- AOD-9604 Guide — optional lipolytic support for stubborn areas
- NAD+ Guide — cofactor support for fat oxidation
- MOTS-c Guide — mitochondrial programming peptide
- MITT-Stack White Paper — mitochondrial peptide deep-dive
- GLP-1 Muscle Preservation — body composition strategies
- Semaglutide Guide — The established GLP-1 benchmark for comparison
- Tirzepatide Guide — Dual-agonist — intermediate between semaglutide and retatrutide
- Reconstitution Guide — How to prepare each vial in the protocol
References
¹ Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023. DOI: 10.1056/NEJMoa2301972
² Stanley TL, et al. Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease. Lancet HIV 2019. DOI: 10.1016/S2352-3018(19)30338-8
³ Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis. Cell Metabolism 2015. DOI: 10.1016/j.cmet.2015.02.009
⁴ Stephens FB, et al. Skeletal Muscle Carnitine Loading Increases Energy Expenditure. Journal of Physiology 2013. DOI: 10.1113/jphysiol.2013.255364
⁵ Yoshino J, et al. NAD+ Intermediates: The Biology and Therapeutic Potential. Cell Metabolism 2021. DOI: 10.1016/j.cmet.2020.11.007
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.